A retrospective nationwide cohort study to investigate
the treatment of diabetes in adults in Norway - DAPHNE
Background/Rationale:
The prevalence of diabetes has been increasing dramatically during the last 50 years, and although no exact number is available, it is estimated that there are approximately 350 000 patients living with diabetes in Norway. Data from the Norwegian prescription registry shows that 170,000 people used anti-diabetic drugs in 2014. A range of new therapeutic modalities have been introduced on the market in the recent years.
Research question and objectives:
The purpose is to explore treatment of diabetic patients in Norway, especially their use of gluocose lowering drugs and to elucidate the patient characteristics for treatment choices as well as the progression of the disease in terms of comorbidities, diabetic complications and drug treatments.
Study design:
Descriptive retrospective study using nationwide data from the Norwegian National Registers.
Study setting and population:
The study population consists of patients over the age of 18 years with a diabetes diagnosis or a prescription dispensed for use of any blood glucose-lowering drugs.
Data sources:
The source population will be identified from the Population Registry (PR) (Statistics Norway), the Norwegian Patient Registry (NPR) or a prescription dispensed of any blood glucose-lowering drugs from the Norwegian Prescription Database (NorPD). Follow-up information will be requested from NPR, NorPD as well as the Norwegian Cause of Death Register (NCoDR) (2004-2014).
Exposure(s): Glucose lowering treatments
Outcome(s):
Patient characteristics (age, gender), co-morbidities (e.g. CVD, GI, cancer), diabetic complications (e.g. nephropathy and neuropathy), mortality, drug utilisation patterns.
News from 2022:
This study uses information collected in national health registers in Norway: The Norwegian Patient Register, the National Prescription Database and The Causes of Death Register. The Regional Ethics Committee has approved exemption from individual informed consent for the studies. In 2022 we have conducted new analyses and published two papers. We will receive updated data in 2023 and perform new analyses that in particular will cover the relationship between heart and kidney failure in patients with and without diabetes.
Publications 2022:
Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD study. Sundström J, Bodegard J, Bollmann A, Vervloet MG, Mark PB, Karasik A, Taveira-Gomes T, Botana M, Birkeland KI, Thuresson M, Jäger L, Sood MM, VanPottelbergh G, Tangri N; CaReMe CKD Investigators.Lancet Reg Health Eur. 2022 Jun 30;20:100438. doi: 10.1016/j.lanepe.2022.100438. eCollection 2022 Sep.PMID: 36090671
Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries. Norhammar A, Bodegard J, Eriksson JW, Haller H, Linssen GCM, Banerjee A, Karasik A, Mamouris P, Tangri N, Taveira-Gomes T, Maggioni AP, Botana M, Thuresson M, Okami S, Yajima T, Kadowaki T, Birkeland KI; CaReMe Cardiorenal Investigators.Diabetes Obes Metab. 2022 Jul;24(7):1277-1287. doi: 10.1111/dom.14698. Epub 2022 Apr 19.PMID: 35322567